Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Novo Nordisk faces negative headlines, but recent share price weakness presents a compelling long-term buying opportunity.

With a market cap of $1 trillion, Eli Lilly and Company (LLY) is one of the world’s leading pharmaceutical innovators, known ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...

An intimate bar and coffee area in the kitchen makes for a suitable backdrop for intimate gatherings, according to its listing. Spacious upper-level bedrooms have Jack-and-Jill baths. Other highlights ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...